Cargando…

Development of replication-competent adenovirus based vaccine vectors

Detalles Bibliográficos
Autores principales:	Abbink, P, Maxfield, LF, Barouch, DH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441744/ http://dx.doi.org/10.1186/1742-4690-9-S2-P310

Ejemplares similares

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

P17-13. Hexon hypervariable regions 4–7 contain important Ad5-specific neutralizing antibody epitopes
por: Bradley, RR, et al.
Publicado: (2009)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

P10-06. Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence
por: Rhee, EG, et al.
Publicado: (2009)

Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein
por: Alexander, J, et al.
Publicado: (2012)

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
por: Li, H, et al.
Publicado: (2012)

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines
por: Ko, S, et al.
Publicado: (2009)

Different memory T cell phenotypes are elicited by Ad5 and rare adenoviruses
por: Penaloza, P, et al.
Publicado: (2012)

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1
por: Stephenson, Kathryn E., et al.
Publicado: (2018)

P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
por: Kaufman, DR, et al.
Publicado: (2009)

P19-37. Replication-defective lymphocytic choriomeningitis virus vectors boost cellular and humoral immunity after DNA or adenovirus vector priming
por: Flatz, LR, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Evaluation of a replication-competent VSV-SIV vaccine candidate
por: Jurgens, CK, et al.
Publicado: (2012)

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following SIV challenges of vaccinated monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

A new strategy for repeated application of adenovirus based vectors: proof-of-concept in rhesus macaques challenged with SIVmac239
por: Sun, C, et al.
Publicado: (2012)

Do humans have replication-competent endogenous retroviruses?
por: Belshaw, Robert, et al.
Publicado: (2009)

Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo
por: Tartaglia, Lawrence J., et al.
Publicado: (2019)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors
por: Crosby, Catherine M., et al.
Publicado: (2017)

P19-35. Replicating adenovirus type 5 host range recombinant vaccine biodistribution in rhesus macaques following multiple mucosal routes of immunization
por: Patterson, J, et al.
Publicado: (2009)

P16-09. Adenovirus 5 vector HIV vaccination does not affect mucosal homing markers on Ad5-specific CD4+ T-cells in humans
por: Hutnick, N, et al.
Publicado: (2009)

Optimization and scale-up of cell culture and purification processes for production of an adenovirus-based tuberculosis vaccine
por: Shen, Chun F, et al.
Publicado: (2015)

Development of nonhuman adenoviruses as vaccine vectors
por: Bangari, Dinesh S., et al.
Publicado: (2006)

Humoral immune response profiling with peptide microarrays
por: Reimer, U, et al.
Publicado: (2012)

Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines
por: Borovjagin, Anton V., et al.
Publicado: (2014)

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C
por: Alexander, Jeff, et al.
Publicado: (2013)

No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants
por: Lee, Dongwoo, et al.
Publicado: (2019)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

P19-07. Development of a protective HIV/SIV vaccine based on a self-boosting cytomegalovirus vector
por: Ambagala, A, et al.
Publicado: (2009)

Adenoviruses as vaccine vectors
por: Tatsis, Nia, et al.
Publicado: (2004)

Vector induced skewing of antibody Fc-effector functions
por: Chung, A, et al.
Publicado: (2012)

Adenovirus Vectors: Excellent Tools for Vaccine Development
por: Chang, Jun
Publicado: (2021)

Single-dose of a replication-competent adenovirus-vectored vaccine provides sterilizing protection against Rift Valley fever virus challenge
por: Bian, Ting, et al.
Publicado: (2022)

Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
por: Capasso, Cristian, et al.
Publicado: (2015)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Engineered microneedle arrays for transcutaneous HIV vaccine delivery
por: DeMuth, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c046pu5iise8bahd209nq5ludo